<DOC>
	<DOCNO>NCT00319189</DOCNO>
	<brief_summary>The objective present study evaluate efficacy safet nateglinide renal transplanta recipient posttransplant diabetes mellitus impaired glucose tolerance . Primarily change glucose tolerance acute insuline responce address .</brief_summary>
	<brief_title>Efficacy Safety Nateglinide Treatment Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<criteria>Reduced glucose tolerance ( fast glucose &lt; 6.1 mmol/L AND 2 hour glucose 6.7 9.9 mmol/L ) posttransplant diabetes mellitus ( fast glucose &gt; 6.1 mmol/L OR 2 hour glucose &gt; = 10.0 mmol/L ) Stable patient fgollowing renal transplantation , le 25 % variation serum creatinine last week serum creatinine &lt; 200 micromol/L Patients indulin dependent diabetes mellitus transplantation Planned change daily prednisolone dose study period Haemoglobin &lt; 8g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Nateglinide</keyword>
	<keyword>Renal</keyword>
	<keyword>Kidney</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Diabets</keyword>
	<keyword>Glucose</keyword>
</DOC>